MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positiv… Read more
MAIA Biotechnology Inc. (MAIA) - Total Liabilities
Latest total liabilities as of September 2025: $11.74 Million USD
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has total liabilities worth $11.74 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MAIA Biotechnology Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how MAIA Biotechnology Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MAIA Biotechnology Inc. Competitors by Total Liabilities
The table below lists competitors of MAIA Biotechnology Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
China | CN¥4.44 Billion |
|
PADAUK Technology Co. Ltd
TWO:6716
|
Taiwan | NT$401.85 Million |
|
Carnaby Resources Ltd
AU:CNB
|
Australia | AU$10.04 Million |
|
Citizens Bancshares Corp
PINK:CZBS
|
USA | $613.64 Million |
|
Bio-FD&C Co. Ltd.
KQ:251120
|
Korea | ₩3.80 Billion |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
India | ₹5.10 Billion |
|
Leo Lithium Limited
PINK:LLLAF
|
USA | $8.07 Million |
|
Plastron Precision Co Ltd
TWO:6185
|
Taiwan | NT$345.06 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down MAIA Biotechnology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 281.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MAIA Biotechnology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MAIA Biotechnology Inc. (2019–2024)
The table below shows the annual total liabilities of MAIA Biotechnology Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.52 Million | -8.02% |
| 2023-12-31 | $7.09 Million | +101.73% |
| 2022-12-31 | $3.51 Million | +63.76% |
| 2021-12-31 | $2.15 Million | -9.18% |
| 2020-12-31 | $2.36 Million | +476.66% |
| 2019-12-31 | $409.74K | -- |